We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Show more
Ask ADVFN Intelligence (AI)
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.45 | 3.60606814225 | 40.21 | 44.65 | 40.21 | 1020314 | 42.8107447 | CS |
| 4 | 1.92 | 4.83140412682 | 39.74 | 44.65 | 35.56 | 786865 | 39.77499349 | CS |
| 12 | 1.22 | 3.01681503462 | 40.44 | 44.65 | 26.2 | 723871 | 37.23597381 | CS |
| 26 | -5.34 | -11.3617021277 | 47 | 50.56 | 26.2 | 649428 | 37.93489223 | CS |
| 52 | 0.81 | 1.98286413709 | 40.85 | 63.5 | 26.2 | 552630 | 42.29776186 | CS |
| 156 | 20.16 | 93.7674418605 | 21.5 | 72.29 | 14.19 | 496832 | 41.49130675 | CS |
| 260 | 20.16 | 93.7674418605 | 21.5 | 72.29 | 14.19 | 496832 | 41.49130675 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
